



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA  
DIPARTIMENTO DI  
SCIENZE MEDICHE E CHIRURGICHE

POLICLINICO DI  
**SANT'ORSOLA**



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Azienda Ospedaliero - Universitaria di Bologna

# New Drugs in Hematology

President: Pier Luigi Zinzani

**Bologna,**  
Royal Hotel Carlton  
**May 18-19-20, 2026**

**BOLOGNA**

**BOLOGNA, ROYAL HOTEL CARLTON**

PROGRAM

## REQUESTED AUSPICES

ALMA MATER STUDIORUM - UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA  
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO  
LE LEUCEMIE - LINFOMI E MIELOMA  
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

## Faculty

Ranjana H.	Advani	Stanford, USA	Jean Marie	Michot	Villejuif, France
Juan Pablo	Alderuccio	Miami, USA	Sattva S.	Neelapu	Houston, USA
Paul M.	Barr	Rochester, USA	Franck E.	Nicolini	Lyon, France
Peter	Borchmann	Cologne, Germany	Francesca	Palandri	Bologna, Italy
Massimo	Breccia	Rome, Italy	Cristina	Papayannidis	Bologna, Italy
Elizabeth	Budde	Duarte, USA	Krish	Patel	Nashville, USA
Carmelo	Carlo-Stella	Rozzano-MI, Italy	Alexander E.	Perl	Philadelphia, USA
Fausto	Castagnetti	Bologna, Italy	Antonio	Pinto	Naples, Italy
Thomas	Cluzeau	Nice, France	Marc	Raab	Heidelberg, Germany
Graham	Collins	London, United Kingdom	Alexandros	Rampotas	London, United Kingdom
Alexey V.	Danilov	Duarte, USA	Delphine	Rea	Paris, France
Naval G.	Daver	Houston, USA	Paula	Rodriguez Otero	Pamplona, Spain
Matthew S.	Davids	Boston, USA	Gilles	Salles	New York, USA
Stephane	De Botton	Villejuif, France	Chiara	Sartor	Bologna, Italy
Adele	De Masson	Paris, France	Stephen J.	Schuster	Philadelphia, USA
Johannes	Düll	Würzburg, Germany	John	Seymour	Melbourne, Australia
Lorenzo	Falchi	New York, USA	Tanya	Siddiqi	Duarte, USA
Sameh R.	Gaballa	Tampa, USA	Yuqin	Song	Beijing, China
Paolo Prospero	Ghia	Milan, Italy	Michele	Spina	Aviano-PN, Italy
Paola	Guglielmelli	Florence, Italy	Paolo	Sportoletti	Perugia, Italy
Henrik	Hjorth-Hansen	Trondheim, Norway	Stephan	Stilgenbauer	Ulm, Germany
Gloria	Iacoboni	Barcelona, Spain	Paolo	Strati	Houston, USA
Swaminathan P.	Iyer	Houston, USA	Marion	Subklewe	Munich, Germany
Elias J.	Jabbour	Houston, USA	Anna	Sureda	Barcelona, Spain
Wojciech	Jurczak	Krakow, Poland	Alessandra	Tedeschi	Milan, Italy
Jonathan	Kaufman	Atlanta, USA	Steven	Treon	Boston, USA
Won Seog	Kim	Seoul, South Korea	Suzanne	Trudel	Toronto, Canada
Marina	Kremyanskaya	New York, USA	Pankit	Vachhani	Birmingham, USA
Nicolaus	Kröger	Hamburg, Germany	Niels	van de Donk	Amsterdam, The Netherlands
Shaji	Kumar	Rochester, USA	Frits	van Rhee	Little Rock, USA
Franco	Locatelli	Rome, Italy	Adriano	Venditti	Rome, Italy
Maurizio	Martelli	Rome, Italy	Michael	Wang	Houston, USA
Thomas	Martin	San Francisco, USA	Elena	Zamagni	Bologna, Italy
Matthew	Matasar	New Brunswick, USA	Pier Luigi	Zinzani	Bologna, Italy
Michael	Mauro	New York, USA			



## Monday, May 18, 2026

09.00 a.m. *Welcome and introduction*

### **SESSION I: A 5-Year look at three amazing therapeutic “SUDOKU puzzle”**

*Chairman: P.L. Zinzani*

09.15 a.m. *Diffuse large B-cell lymphoma - G. Salles*

09.40 a.m. *Multiple myeloma - S. Kumar*

10.05 a.m. *Chronic lymphocytic leukemia - S. Stilgenbauer*

### **SESSION II: CAR-T**

*Chairman: S.J. Schuster*

10.30 a.m. *Second generation auto-CAR-T - S.J. Schuster*

10.50 a.m. *Allogeneic CAR-T: do they have a real future? - S.S. Neelapu*

11.10 a.m. *In vivo CAR-T - T. Siddiqi*

### **SESSION III: News in Hodgkin's lymphoma**

*Chairman: A. Sureda*

11.30 a.m. *Actual scenario in frontline advanced stage - P. Borchmann*

11.45 a.m. *With the therapeutic revolution in first line, how will the second line be modified? - A. Sureda*

12.00 p.m. *New agents in R/R patients - R.H. Advani*

12.15 p.m. *The therapeutic algorithm for elderly and “old old” patients - G. Collins*

12.30 p.m. *CAR-T: can we see the light at the end of the tunnel? - F. Locatelli*

01.00 p.m. *Lunch*

### **LECTURES: update on BTK/BCL6 degraders**

*Chairman: P.L. Zinzani*

02.00 p.m. *ZelevrudoMIDE (NX-2127) and bexobrutideG (NX-5948) - A.V. Danilov*

02.15 p.m. *BGB-16673 - J. Seymour*

02.30 p.m. *Bifunctional cereblon-dependent ligand-directed degrader of B cell lymphoma 6 - G. Salles*

### **SESSION IV: Acute leukemias**

*Chairman: A. Venditti*

02.50 p.m. *BCL-2 inhibitors in AML: venetoclax and beyond - T. Cluzeau*

03.05 p.m. *Antibody-drug conjugates in AML: novel targets for novel drugs - C. Sartor*

03.20 p.m. *Triplet therapy in AML: a myth or the next frontier - N.G. Daver*

03.35 p.m. *IDH inhibitors in AML - S. De Botton*

04.00 p.m. *Coffee break*

04.30 p.m. *Targeting FLT3: how to choose among inhibitors - A.E. Perl*

04.45 p.m. *Menin-inhibitors in AML and ALL - C. Papayannidis*

05.00 p.m. *Immunotherapies in AML and ALL - M. Subklewe*

05.15 p.m. *BCL-2 inhibition in ALL - E.J. Jabbour*

**SESSION V: Classical Ph1-neg myeloproliferative neoplasms**

Chairmen: *P. Guglielmelli, F. Palandri*

- 08.30 a.m. Interferons and epigenetic modulators: redefining the therapeutic landscape in PV - *F. Palandri*
- 08.45 a.m. Iron metabolism modifiers in PV - *M. Kremyanskaya*
- 09.00 a.m. Evolving strategies for cytopenic myelofibrosis - *P. Guglielmelli*
- 09.15 a.m. Epigenetic modifiers and pro-apoptotic agents in myelofibrosis - *P. Vachhani*
- 09.30 a.m. Monoclonal and bispecific antibodies targeting mutant CALR - *A. Rampotas*
- 09.45 a.m. Best timing and patient selection for allogeneic transplantation in MF - *N. Kröger*
- 10.10 p.m. *Coffee break*

**SESSION VI: Non-Hodgkin's lymphoma (I)**

Chairman: *C. Carlo-Stella*

Bispecific antibodies in combinations

- 10.30 a.m. Epcoriab - *L. Falchi*
- 10.45 a.m. Glofitamab - *G. Iacoboni*
- 11.00 a.m. Mosunetuzumab - *E. Budde*
- 11.15 a.m. Odronextamab - *W.S. Kim*

New bispecific and trispecific antibodies

- 11.30 a.m. Surovatamig - *S. Gaballa*
- 11.45 a.m. BAFFR bispecific - *K. Patel*
- 12.00 p.m. Trispecific antibodies - *M. Subklewe*

Monoclonal antibodies and ADC combinations

- 12.15 p.m. Tafasitamab combinations - *J. Düll*
- 12.30 p.m. Loncastuximab combinations - *J.P. Alderuccio*
- 12.45 p.m. Polatuzumab combinations - *M. Matasar*

01.15 p.m. *Lunch*

**SESSION VII: Non-Hodgkin's lymphoma (II)**

Chairman: *M. Martelli*

BTK inhibitors combinations

- 02.15 p.m. Ibrutinib - *K. Patel*
- 02.30 p.m. Zanubrutinib - *P.L. Zinzani*
- 02.45 p.m. Acalabrutinib - *P. Strati*
- 03.00 p.m. Pirtobrutinib - *M. Wang*

BCL-2 inhibitors

- 03.15 p.m. Sonrotoclax - *M. Wang*

**SESSION VIII: Non-Hodgkin's lymphoma (III)**

Chairmen: *A. Pinto, M. Spina*

- 03.30 p.m. DZD8586, a non-covalent BBB penetrant LYN/BTK inhibitor - *Y. Song*
- 03.45 p.m. Golcadomide - *J.M. Michot*
- 04.00 p.m. Mogamulizumab in combinations - *A. De Masson*
- 04.15 p.m. Zeprumetostat (SHR2554) - *Y. Song*
- 04.30 p.m. Dibotatug (DR-01) - *S.P. Iyer*

## **SESSION IX: Chronic myeloid leukemia**

*Chairman: F. Castagnetti*

- 04.45 p.m. CML treatment recommendations - *H. Hjorth-Hansen*
- 05.00 p.m. Asciminib - *M. Breccia*
- 05.15 p.m. Ponatinib - *F. Castagnetti*
- 05.30 p.m. Vodobatinib - *F.E. Nicolini*
- 05.45 p.m. Olverembatinib - *D. Rea*
- 06.00 p.m. TERN-701, ELVN-001 and other new agents - *M. Mauro*

## **Wednesday, May 20, 2026**

### **LECTURES**

*Chairman: A. Tedeschi*

- 08.30 a.m. Novel therapies for Waldenström's macroglobulinemia - *S. Treon*
- 08.50 a.m. News from Castleman disease - *F. van Rhee*

## **SESSION X: Chronic lymphocytic leukemia**

*Chairmen: P. Sportoletti, A. Tedeschi*

- 09.15 a.m. First line:
  - Until the progression - *S. Stilgenbauer*
  - Fixed duration - *M.S. Davids*

- 09.45 a.m. **Round table: analyzing the guide lines!**

*Chairman: P. Ghia*

*Discussants: P.M. Barr, M.S. Davids, W. Jurczak, S. Stilgenbauer*

- 10.30 a.m. Pirtobrutinib - *P.M. Barr*

- 10.45 a.m. Novel agents - *W. Jurczak*

## **SESSION XI: Multiple myeloma**

*Chairmen: J. Kaufman, E. Zamagni*

- 11.15 a.m. New CARTs in relapsed/refractory patients - *T. Martin*

- 11.30 a.m. Bispecifics against BCMA and GPRC5D in relapsed/refractory patients - *P. Rodriguez Otero*

- 11.45 a.m. Bispecifics in combination and trispecifics in relapsed/refractory patients - *N. van de Donk*

- 12.00 p.m. Moving forward: immunotherapies in newly diagnosed - *M. Raab*

- 12.15 p.m. Celmods alone and in combination in newly diagnosed and relapsed/refractory patients - *J. Kaufman*

- 12.30 p.m. ADC combinations in newly diagnosed and relapsed/refractory patients - *S. Trudel*

- 01.00 p.m. Arrivederci

## GENERAL INFORMATION

### MEETING VENUE

#### Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy  
www.royalhotelcarltonbologna.com

### OFFICIAL LANGUAGE

English

### REGISTRATION

Registration is available at [www.ercongressi.it](http://www.ercongressi.it) - section "I nostri congressi/anno 2026"

The registration includes conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

### BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

### ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-472999
- **No. 6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology).
- Educational objective: "linee guida-protocolli-procedure".

### EUROPEAN CME CREDITS

The program of the "New Drugs in Hematology" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 19,5 CME credits for Physicians. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

### CHANGES

Parts of the program may be changed without notice.

## ACKNOWLEDGEMENTS

With the unrestricted educational grant of

abbvie

AstraZeneca 

 BeOne

 Bristol Myers Squibb®

Johnson & Johnson

 GILEAD |  Kite

 GSK

 KARTOS THERAPEUTICS™

 Lilly  
A MEDICINE COMPANY

 Roche

 Incyte |  SOLVE ON.

 Daiichi-Sankyo

 MENARINI Stemline

 NURIX™

 REGENERON  
SCIENCE TO MEDICINE®

 sobi

 Takeda

# New Drugs in Hematology

## Scientific Secretariat

Pier Luigi Zinzani  
Istituto di Ematologia  
“Lorenzo e Ariosto Seràgnoli”  
Via Massarenti, 9 - 40138 Bologna, Italy

## Organizing Secretariat

Studio E.R. Congressi  
Via De' Poeti 1/7 - 40124 Bologna, Italy  
Phone +39 051 4210559  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)

ER Congressi

